- Leveljump Healthcare Corp. (JUMP) has acquired a further 260,000 shares or 10.8 per cent of Shaw Vision and Shaw Lens
- The Shaw Acquisition has been approved by the boards of Shaw Vision and Shaw Lens
- The purchase price for the Shaw shares was $104,000 or $0.20 per share
- Leveljump now owns 34.6 per cent of each of Shaw Vision and Shaw Lens and is the largest shareholder in each company
- Leveljump Healthcare is a Canadian leader in business-to-business (B2B) telehealth solutions
- LevelJump Healthcare Corp. (JUMP) remains unchanged at $0.175 at 11:13 AM ET
Leveljump Healthcare Corp. (JUMP) has acquired 260,000 shares of each of Shaw Vision Inc. and Shaw Lens Inc. from minority shareholders.
The acquisition has been approved by the boards of both Shaw Vision and Shaw Lens.
The purchase price for the shares was $104,000 or $0.20 per share.
Leveljump now owns 34.6 per cent of Shaw Vision and Shaw Lens and is the largest shareholder in each company.
Both Shaw Vision Inc. and Shaw Lens Inc. are Toronto-based privately owned corporations.
Shaw Lens holds a U.S. patent-protected lens technology that can solve a condition for people who wear glasses, known as aniseikonia.
It is a condition that causes each eye to perceive the size of objects differently. Issues related can include headaches, double vision, disorientation or dizziness, tearing, eye pain or fatigue, sensitivity to light, visual acuity issues and trouble reading, as well as nausea,
According to the Columbia University Department of Ophthalmology, “20-30 per cent of the general spectacle-wearing population may have a measurable amount of aniseikonia.”
The potential market size for corrective lenses for aniseikonia is over 800 million people that may be currently living with some degree of aniseikonia and its relative effects.
Leveljump Healthcare Corp. is a Canadian leader in business-to-business (B2B) telehealth solutions.
LevelJump Healthcare Corp. (TSXV:JUMP) remains unchanged at $0.175 at 11:13 AM ET.
